

CHANGE OF AUDITOR

MELBOURNE Australia, 10 July 2020 – Prescient Therapeutics (ASX: PTX) (**'Prescient Therapeutics'** or **'Company'**) advises that in accordance with Listing Rule 3.16.3 that William Buck Audit (Vic) Pty Ltd (**'William Buck'**) has been appointed as auditor of the Company. The appointment follows the resignation of Ernst & Young as the Company's auditor and ASIC's consent to the resignation in accordance with s 329(5) of the Corporations Act 2001 (**'Act'**).

In accordance with s 327C of the Act, a resolution will be proposed at the Company's 2020 Annual General Meeting to confirm the appointment of William Buck as the Company's auditor.

– Ends –

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Cell Therapy: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.



Find out more at ptxtherapeutics.com, or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](#).

The Board of Prescient Therapeutics Limited have approved the release of this announcement.

For more information please contact:

Melanie Leydin
Company Secretary
Prescient Therapeutics
mleydin@leydinfreyer.com.au

Investor enquiries:
Warrick Lace – Reach Markets
+61 404 656 408
warrick.lace@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)